Hologic (HOLX) Stock Price

Hologic Price

Delisted·Apr 7, 2026
76.01USD-0.05 (-0.06 %)
Last traded price

Over the last 19 years Hologic grew revenue by 12.2% annually, reaching 4.10 B USD. Earnings per share have grown at 12.1% per year over the last 19 years. For Hologic, the net margin of 13.8% is down versus 33.2% a few years ago. The consensus 12-month price target for Hologic is 77.52 USD, about 2.0% above where the stock trades today. Of 23 analysts, 0 rate the stock a buy — an overall Hold consensus. The stock trades about 20% above its 52-week low.

Hologic stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Hologic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hologic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hologic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Hologic Stock Price History
DateHologic Price
4/7/202676.01 USD
4/6/202676.06 USD
4/2/202675.65 USD
4/1/202675.60 USD
3/31/202675.59 USD
3/30/202675.55 USD
3/27/202675.67 USD
3/26/202675.69 USD
3/25/202675.52 USD
3/24/202675.55 USD
3/23/202675.64 USD
3/20/202675.41 USD
3/19/202675.33 USD
3/18/202675.33 USD
3/17/202675.05 USD
3/16/202675.15 USD
3/13/202675.18 USD
3/12/202675.21 USD
3/11/202675.37 USD
3/10/202675.54 USD
3/9/202675.59 USD
3/6/202675.74 USD
3/5/202675.75 USD
3/4/202675.67 USD
3/3/202675.46 USD
3/2/202675.45 USD
2/27/202675.36 USD
2/26/202675.23 USD
2/25/202675.34 USD
2/24/202675.35 USD
2/23/202675.44 USD
2/20/202675.43 USD
2/19/202675.14 USD
2/18/202675.20 USD
2/17/202675.15 USD
2/13/202675.04 USD
2/12/202674.91 USD
2/11/202675.09 USD
2/10/202675.15 USD
2/9/202675.02 USD
2/6/202674.81 USD
2/5/202674.70 USD
2/4/202674.59 USD
2/3/202674.63 USD
2/2/202674.74 USD
1/30/202674.93 USD
1/29/202674.98 USD
1/28/202675.10 USD
1/27/202675.20 USD
1/26/202675.19 USD
1/23/202675.05 USD
1/22/202675.11 USD
1/21/202675.16 USD
1/20/202675.13 USD
1/16/202674.98 USD
1/15/202675.02 USD
1/14/202675.16 USD
1/13/202674.87 USD
1/12/202674.86 USD
1/9/202674.89 USD
1/8/202674.88 USD
1/7/202674.96 USD
1/6/202674.91 USD
1/5/202674.75 USD
1/2/202674.56 USD
12/31/202574.49 USD
12/30/202574.54 USD
12/29/202574.51 USD
12/26/202574.50 USD
12/24/202574.50 USD
12/23/202574.87 USD
12/22/202574.91 USD
12/19/202574.95 USD
12/18/202574.94 USD
12/17/202574.93 USD
12/16/202575.02 USD
12/15/202575.19 USD
12/12/202575.00 USD
12/11/202574.83 USD
12/10/202574.83 USD
12/9/202574.89 USD
12/8/202574.85 USD
12/5/202574.97 USD
12/4/202574.86 USD
12/3/202575.01 USD
12/2/202574.82 USD
12/1/202574.84 USD
11/28/202574.97 USD
11/26/202574.80 USD
11/25/202574.88 USD
11/24/202574.76 USD
11/21/202574.36 USD
11/20/202574.12 USD
11/19/202574.17 USD
11/18/202574.15 USD
11/17/202574.14 USD
11/14/202574.15 USD
11/13/202574.26 USD
11/12/202574.56 USD
11/11/202574.60 USD
11/10/202574.30 USD
11/7/202574.10 USD
11/6/202574.15 USD
11/5/202574.23 USD
11/4/202574.11 USD
11/3/202574.27 USD
10/31/202573.94 USD
10/30/202573.93 USD
10/29/202573.98 USD
10/28/202574.01 USD
10/27/202573.95 USD
10/24/202574.02 USD
10/23/202573.89 USD
10/22/202573.93 USD
10/21/202573.98 USD
10/20/202571.87 USD
10/17/202573.52 USD
10/16/202568.52 USD
10/15/202567.00 USD
10/14/202565.92 USD
10/13/202565.51 USD
10/10/202566.52 USD
10/9/202568.62 USD
10/8/202568.34 USD
10/7/202567.73 USD
10/6/202567.34 USD
10/3/202568.36 USD
10/2/202567.91 USD
10/1/202567.04 USD
9/30/202567.49 USD
9/29/202567.15 USD
9/28/202567.15 USD
9/25/202567.21 USD
9/24/202565.79 USD
9/23/202567.64 USD
9/22/202567.29 USD
9/19/202566.31 USD
9/18/202568.27 USD
9/17/202567.22 USD
9/16/202563.33 USD
9/15/202563.80 USD
9/12/202564.58 USD
9/11/202566.38 USD
9/10/202565.51 USD
9/9/202566.72 USD
9/8/202566.54 USD
9/5/202566.78 USD
9/4/202566.39 USD
9/3/202566.24 USD
9/2/202566.61 USD
8/29/202567.14 USD
8/28/202566.62 USD
8/27/202566.73 USD
8/26/202566.63 USD
8/25/202567.13 USD
8/22/202568.67 USD
8/21/202567.17 USD
8/20/202568.76 USD
8/19/202567.82 USD
8/18/202567.27 USD
8/15/202567.88 USD
8/14/202568.06 USD
8/13/202568.98 USD
8/12/202567.95 USD
8/11/202567.99 USD
8/8/202567.90 USD
8/7/202567.93 USD
8/6/202566.89 USD
8/5/202567.82 USD
8/4/202567.91 USD
7/31/202567.16 USD
7/30/202566.82 USD
7/29/202564.98 USD
7/28/202566.04 USD
7/27/202565.69 USD
7/25/202566.37 USD
7/24/202566.10 USD
7/23/202565.95 USD
7/22/202565.39 USD
Access this data via the Eulerpool API
Get Free API Key

Hologic Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
4.03 B USD
941.00 M USD
456.00 M USD
Jan 1, 2024
4.03 B USD
970.20 M USD
789.50 M USD
Jan 1, 2025
4.10 B USD
1.07 B USD
565.70 M USD
Jan 1, 2026 (e)
4.30 B USD
1.27 B USD
1.02 B USD
Jan 1, 2027 (e)
4.51 B USD
1.33 B USD
1.12 B USD
Jan 1, 2028 (e)
4.72 B USD
1.38 B USD
1.20 B USD
Jan 1, 2029 (e)
5.05 B USD
1.59 B USD
1.31 B USD
Jan 1, 2030 (e)
5.36 B USD
0.00 USD
1.35 B USD

Hologic Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 22, 2026, 11:04 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
2.833.063.223.373.785.634.864.034.034.104.304.514.725.055.365.49
4.707.985.204.6612.1549.15-13.67-17.11–1.744.765.034.596.936.242.44
55.1953.0152.7251.9559.6767.3861.9955.8656.2556.3456.3456.3456.3456.3456.3456.34
1.561.621.701.752.253.803.012.252.272.312.422.542.662.843.023.09
0.560.480.510.571.152.481.650.940.971.071.271.331.381.59––
19.7415.7915.7916.8730.4644.0733.9023.3524.0726.0529.5929.4229.2731.48––
0.330.76-0.11-0.201.121.871.300.460.790.571.021.121.201.311.351.62
151.91128.79-114.7082.88-649.2667.80-30.41-64.9873.03-28.3981.069.197.349.262.7519.99
286.20285.70275.10269.40264.60259.70253.80248.83237.55227.57227.57227.57227.57227.57227.57227.57
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Hologic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hologic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hologic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Hologic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hologic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Hologic stock margins

The Hologic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hologic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hologic.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
67.39 %
44.08 %
33.23 %
Jan 1, 2022
62.00 %
33.89 %
26.77 %
Jan 1, 2023
55.85 %
23.35 %
11.31 %
Jan 1, 2024
56.25 %
24.07 %
19.59 %
Jan 1, 2025
56.35 %
26.06 %
13.80 %
Jan 1, 2026 (e)
56.35 %
29.59 %
23.84 %
Jan 1, 2027 (e)
56.35 %
29.42 %
24.77 %
Jan 1, 2028 (e)
56.35 %
29.27 %
25.42 %

Hologic Stock Revenue, EBIT, Earnings per Share

The Hologic earnings per share therefore indicates how much revenue Hologic has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
21.69 USD
9.56 USD
7.21 USD
Jan 1, 2022
19.16 USD
6.49 USD
5.13 USD
Jan 1, 2023
16.20 USD
3.78 USD
1.83 USD
Jan 1, 2024
16.97 USD
4.08 USD
3.32 USD
Jan 1, 2025
18.02 USD
4.70 USD
2.49 USD
Jan 1, 2026 (e)
18.87 USD
5.59 USD
4.50 USD
Jan 1, 2027 (e)
19.82 USD
5.83 USD
4.91 USD
Jan 1, 2028 (e)
20.73 USD
6.07 USD
5.27 USD

Hologic business model & stock analysis

Hologic Inc. is a company from the United States that has established itself in the medical technology market. The company was founded in 1985 by Jay A. Stein, who set the goal of developing products and services that contribute to improving people's lives. Hologic specializes in artificial intelligence (AI) based diagnostic and therapeutic technology that increases the safety, effectiveness, and accuracy of medical procedures. The company initially focused on products in the field of mammography, but has since expanded to various sectors including imaging, gynecology, skeletal, and surgery. Hologic offers its customers products such as tomosynthesis systems, robot-assisted surgery systems, image analysis software, and a variety of reagents, kits, and tests. The company's business model is focused on innovative technology and science, aiming to optimize medical interventions and thus reduce and improve healthcare costs. Hologic is dedicated to research and development and has already filed dozens of patents. In the field of breast cancer diagnostics, Hologic has developed various mammography systems that have broken the standard of mammography. Through the use of tomosynthesis, a 3D-based diagnostic, it is possible to detect tumors and malignant changes earlier. This procedure has been widely used by many doctors around the world and has proven to be a reliable method for early detection of breast cancer. In gynecology, Hologic specializes in the development of diagnostic tests for infectious agents and hormones. The tests, such as the Aptima HPV test, are fast, sensitive, and reliable. They help to detect infectious agents earlier and initiate appropriate therapy. Hologic Taurus, a robot-assisted surgery system, has been developed to enable minimally invasive interventions that can be used to treat uterine fibroids. This method allows for a drastic reduction in hospital stay duration and recovery time. In the field of skeletal, Hologic offers various systems that are helpful in the diagnosis and treatment of osteoporosis. The widely used DXA system (Dual-Energy X-Ray Absorptiometer) is still one of the most accurate devices for measuring bone density. Additionally, Hologic is an company that not only focuses on medical technology but also pursues the larger goal of improving people's lives. An example of this is their partnership with the organization Pink Ribbon, which serves as a global ambassador for breast cancer early detection. Hologic has developed a special mammography system called Pink Affirm. For every system sold, Hologic donates a certain amount to Pink Ribbon. Overall, Hologic Inc. has become an important player in the field of medical technology and diagnostics. Through its innovative technologies and products, the company contributes to improving the health and lives of people worldwide.

Hologic SWOT Analysis

Strengths

Hologic Inc has several strengths that contribute to its success in the market. These strengths include:

  • Strong brand reputation and recognition in the healthcare industry
  • Wide range of innovative and high-quality medical devices and diagnostic solutions
  • Strong financial performance and revenue growth
  • Strong distribution network and global presence
  • Commitment to research and development, leading to continuous product advancements

Weaknesses

Hologic Inc also has weaknesses that pose some challenges to the company. These weaknesses include:

  • Relatively high production costs leading to higher product prices
  • Dependence on a limited number of key suppliers for crucial components
  • Limited diversification in terms of product portfolio
  • Risk of regulatory changes affecting the healthcare industry

Opportunities

Despite the weaknesses, there are also opportunities for Hologic Inc to capitalize on. These opportunities include:

  • Increased demand for advanced medical devices and diagnostic solutions
  • Expansion into emerging markets with a growing healthcare sector
  • Partnerships or acquisitions to enhance product portfolio diversification
  • Technological advancements in the healthcare industry opening new possibilities

Threats

Hologic Inc faces certain threats that could negatively impact its business. These threats include:

  • Intense competition from other major players in the medical device industry
  • Changing regulatory environment and potential legal hurdles
  • Economic downturn and reduced healthcare spending
  • Emergence of substitute products or technologies

Hologic Segments

Hologic Revenue by Segment (1/7)

  • 3 Years

  • 5 Years

  • Max

Service
Details
Date
Service
Jan 1, 2018
0.00 USD
Jan 1, 2019
568.30 M USD
Jan 1, 2020
516.60 M USD
Jan 1, 2021
598.10 M USD
Jan 1, 2022
652.40 M USD
Jan 1, 2023
730.50 M USD
Jan 1, 2024
758.20 M USD
Jan 1, 2025
825.50 M USD

Hologic Revenue by Segment (2/7)

  • 3 Years

  • 5 Years

  • Max

Molecular Diagnostics
Breast Imaging
Cytology & Perinatal
Interventional Breast Solutions
Blood Screening
Details
Date
Molecular Diagnostics
Breast Imaging
Cytology & Perinatal
Interventional Breast Solutions
Blood Screening
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
58.50 M USD
Jan 1, 2020
1.65 B USD
953.60 M USD
410.10 M USD
198.30 M USD
43.60 M USD
Jan 1, 2021
3.17 B USD
1.08 B USD
473.90 M USD
268.90 M USD
49.60 M USD
Jan 1, 2022
2.51 B USD
951.60 M USD
474.70 M USD
276.20 M USD
32.40 M USD
Jan 1, 2023
1.36 B USD
1.14 B USD
480.60 M USD
288.50 M USD
37.80 M USD
Jan 1, 2024
1.27 B USD
1.21 B USD
479.20 M USD
312.20 M USD
30.30 M USD
Jan 1, 2025
1.31 B USD
1.11 B USD
488.60 M USD
374.60 M USD
28.20 M USD

Hologic Revenue by Segment (3/7)

  • 3 Years

  • 5 Years

  • Max

Disposables
Consumables
Molecular Diagnostics
Breast Imaging
Capital equipment, components and software
Cytology & Perinatal
Interventional Breast Solutions
Other
Details
Date
Disposables
Consumables
Molecular Diagnostics
Breast Imaging
Capital equipment, components and software
Cytology & Perinatal
Interventional Breast Solutions
Other
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
675.00 M USD
1.09 B USD
0.00 USD
472.00 M USD
219.60 M USD
0.00 USD
Jan 1, 2020
0.00 USD
2.56 B USD
0.00 USD
0.00 USD
665.90 M USD
0.00 USD
0.00 USD
32.80 M USD
Jan 1, 2021
0.00 USD
4.20 B USD
0.00 USD
0.00 USD
769.10 M USD
0.00 USD
0.00 USD
66.90 M USD
Jan 1, 2022
0.00 USD
3.60 B USD
0.00 USD
0.00 USD
587.60 M USD
0.00 USD
0.00 USD
19.20 M USD
Jan 1, 2023
0.00 USD
2.54 B USD
0.00 USD
0.00 USD
740.50 M USD
0.00 USD
0.00 USD
20.00 M USD
Jan 1, 2024
2.49 B USD
0.00 USD
0.00 USD
0.00 USD
764.90 M USD
0.00 USD
0.00 USD
17.00 M USD
Jan 1, 2025
2.62 B USD
0.00 USD
0.00 USD
0.00 USD
638.40 M USD
0.00 USD
0.00 USD
18.90 M USD

Hologic Revenue by Segment (4/7)

  • 3 Years

  • 5 Years

  • Max

Consumables
Capital equipment, components and software
Other
Details
Date
Consumables
Capital equipment, components and software
Other
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
1.79 B USD
984.90 M USD
27.70 M USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Hologic Revenue by Segment (5/7)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Diagnostics
Breast Health
Gyn Surgical
Medical Aesthetics
Skeletal Health
Details
Date
Diagnostics
Breast Health
Gyn Surgical
Medical Aesthetics
Skeletal Health
Jan 1, 2018
1.15 B USD
1.22 B USD
422.00 M USD
339.10 M USD
91.20 M USD
Jan 1, 2019
1.21 B USD
1.31 B USD
437.20 M USD
315.60 M USD
94.80 M USD
Jan 1, 2020
2.10 B USD
1.15 B USD
376.10 M USD
0.00 USD
81.00 M USD
Jan 1, 2021
3.70 B USD
1.35 B USD
488.10 M USD
0.00 USD
96.90 M USD
Jan 1, 2022
3.02 B USD
1.23 B USD
522.90 M USD
0.00 USD
93.60 M USD
Jan 1, 2023
1.88 B USD
1.43 B USD
604.20 M USD
0.00 USD
113.40 M USD
Jan 1, 2024
1.78 B USD
1.52 B USD
641.30 M USD
0.00 USD
84.10 M USD
Jan 1, 2025
1.83 B USD
1.48 B USD
679.80 M USD
0.00 USD
109.40 M USD

Hologic Revenue by Segment (6/7)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Diagnostics
Breast Health
Medical Aesthetics
Details
Date
Diagnostics
Breast Health
Medical Aesthetics
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
65.30 M USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Hologic Revenue by Segment (7/7)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Diagnostics
Breast health
GYN surgical
Skeletal health
Details
Date
Diagnostics
Breast health
GYN surgical
Skeletal health
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Hologic Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
International
Europe
Asia-Pacific
Details
Date
United States
International
Europe
Asia-Pacific
Jan 1, 2019
2.54 B USD
831.30 M USD
396.00 M USD
286.00 M USD
Jan 1, 2020
2.86 B USD
913.20 M USD
569.80 M USD
226.80 M USD
Jan 1, 2021
3.90 B USD
1.73 B USD
1.20 B USD
365.00 M USD
Jan 1, 2022
3.47 B USD
1.39 B USD
888.50 M USD
359.70 M USD
Jan 1, 2023
3.06 B USD
972.40 M USD
520.30 M USD
255.70 M USD
Jan 1, 2024
3.02 B USD
1.01 B USD
532.70 M USD
259.60 M USD
Jan 1, 2025
3.05 B USD
1.05 B USD
591.00 M USD
243.30 M USD

Hologic Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Hologic historical P/E ratio, EBIT multiple, and P/S ratio

Hologic annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Hologic shares outstanding

The number of shares of Hologic was 227.57 M in 2025. This indicates how many shares Hologic is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
259.70 M Stocks
Jan 1, 2022
253.80 M Stocks
Jan 1, 2023
248.83 M Stocks
Jan 1, 2024
237.55 M Stocks
Jan 1, 2025
227.57 M Stocks
Jan 1, 2026 (e)
227.57 M Stocks
Jan 1, 2027 (e)
227.57 M Stocks
Jan 1, 2028 (e)
227.57 M Stocks

Hologic stock splits

In Hologic's history, there have been no stock splits.

Current Hologic forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy0.00 % (0)
Hold86.96 % (20)
Sell13.04 % (3)
12M Price Target
77.52
Last Price
76.01
Currency
USD
12M Return Potential
1.99 %
LTM Return
0 %

Hologic Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
7/28/20261.13USD1.07 BUSD2026 Q3
4/30/20261.08USD1.05 BUSD2026 Q2
2/4/20261.11USD1.09 BUSD2026 Q1
1/29/20261.11USD1.09 BUSD2026 Q1
11/7/20241.03USD997.29 MUSD2024 Q4
4/29/20241.00USD1.02 BUSD2024 Q2
1/30/20240.96USD995.56 MUSD2024 Q1
7/25/20230.89USD971.85 MUSD2023 Q3
4/25/20230.84USD937.40 MUSD2023 Q2
1/31/20230.88USD980.84 MUSD2023 Q1
...

EESG©

Eulerpool ESG Scorecard© for the Hologic stock

74/100
60
Environment
77
Social
85
Governance
E

Environment

20
Scope 1 - Direct Emissions7,050
Scope 2 - Indirect emissions from purchased energy14,705
Scope 3 - Indirect emissions within the value chain470,680
Total CO₂ emissions21,755
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees42
Percentage of women in management—
Percentage of Asian employees15
Share of Asian management—
Percentage of Hispanic/Latino employees9
Hispano/Latino Management share—
Percentage of Black employees5
Black Management Share—
Percentage of white employees64
White Management Share74
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hologic shareholder structure

% Name
11.41821%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.65080%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.33956%
State Street Investment Management (US)
State Street Investment Management (US)
4.14893%
Manulife Investment Management (North America) Limited
Manulife Investment Management (North America) Limited
3.69112%
HBK Investments, L.P.
HBK Investments, L.P.
2.60677%
T. Rowe Price Investment Management, Inc.
T. Rowe Price Investment Management, Inc.
...

Hologic Executives and Management Board

SM

Mr. Stephen Macmillan

(61)

Chairman of the Board, President, Chief Executive Officer · since 2013

Compensation15.93 M USD
EM

Mr. Essex Mitchell

(46)

Chief Operating Officer

Compensation5.08 M USD
KO

Ms. Karleen Oberton

(56)

Chief Financial Officer · since 2018

Compensation4.39 M USD
JV

Mr. Jan Verstreken

(58)

Group President - International

Compensation3.46 M USD
JS

Dr. Jennifer Schneiders

(58)

President - Diagnostic Solutions

Compensation3.13 M USD

Hologic Supply Chain

Hologic Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
25 companies
#Name1M3M6M1Y2YTrend
1
Flex Ltd.
Supplier
0.57
0.60
0.37
0.09
0.69
2
STRATEC
Supplier
0.89
0.72
0.40
0.54
0.68
3
General Electric
Supplier
0.74
0
-0.09
-0.35
0.50
4
discoverIE Group plc
Supplier
-0.01
0.01
0.10
0.35
0.46
5
Varex Imaging Corporation
Supplier
0.84
-0.51
-0.05
0.08
0.44
#Name1M3M6M1Y2YTrend
1
ON24, Inc.
Supplier
0.76
-0.14
0
-0.50
—
2
Grifols, S.A.
0.12
-0.70
-0.18
—
—
3
9342-8530 Quebec
Supplier
-0.07
—
—
—
—
4
Seegene, Inc.
Supplier
0.70
-0.46
-0.08
-0.62
—
5
Tecan Group Ltd.
Supplier
0.73
0.68
—
—
—

Frequently asked questions about Hologic

The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.

All fundamentals and in-depth analysis of Hologic

Our stock analysis for Hologic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hologic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Hologic Stock
Hologic Revenue→
Hologic Stock
Hologic Net Income→
Hologic Stock
Hologic P/E→
Hologic Stock
Hologic P/S→
Hologic Stock
Hologic EBIT→
Hologic Stock
Hologic Dividend→
Hologic Stock
Hologic Directors Dealings→
Hologic Stock
Hologic Stocks→
Hologic Stock
Hologic Market capitalization→
Hologic Stock
Hologic Debt→
Hologic Stock
Hologic Liabilities→
Hologic Stock
Hologic Equity→
Hologic Stock
Hologic AAQS→
Hologic Stock
Hologic Employees→
Hologic Stock
Hologic ROE→
Hologic Stock
Hologic ROA→
Hologic Stock
Hologic ROCE→
Hologic Stock
Hologic News→
Hologic Stock
Hologic Analyst Price Targets→